FILE - This Monday, April 6, 2020 file photo shows an arrangement of hydroxychloroquine pills in Las Vegas. On Friday, June 5, 2020, leaders of a large study in the United Kingdom that is rigorously testing the malaria drug hydroxychloroquine and other medicines for hospitalized COVID-19 patients say they will stop putting people on the drug because it’s clear it isn’t helping. (AP Photo/John Locher)

WHO ending hydroxychloroquine trial for COVID-19

WHO says the decision won't affect possible trials on patients who aren't hospitalized

  • Jul. 5, 2020 12:00 a.m.

The World Health Organization says it is ending a trial into whether anti-malaria drug hydroxychloroquine helps patients hospitalized with COVID-19.

WHO said Saturday it has “accepted the recommendation” from the committee overseeing the trial to discontinue testing of hydroxychloroquine and lopinavir/ritonavir, a drug combination used to treat HIV/AIDS. The drugs were being compared with standard care for hospitalized patients.

WHO says a review of the interim results showed hydroxychloroquine and lopinavir/ritonavir “produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care.”

The agency adds that while there was no “solid evidence” of increased mortality for hospitalized patients given the drugs, there were “some associated safety signals in the clinical laboratory findings” of an associated trial.

WHO says the decision won’t affect possible trials on patients who aren’t hospitalized, or on those receiving the drugs before potential exposure to the coronavirus or shortly afterward.

PHOTOS: B.C.’s top doc picks up personalized Fluevog shoes, tours mural exhibition

The Associated Press


Like us on Facebook and follow us on Twitter.

Want to support local journalism during the pandemic? Make a donation here.

Abbotsford News

Just Posted

Most Read